Vilka är öppettiderna?

Måndag 09:00 - 17:00 Tisdag 09:00 - 17:00 Onsdag 09:00 - 17:00 Torsdag 09:00 - 17:00 Fredag 09:00 - 17:00

Uppsala Monitoring Centre

Hem
Sverige
Uppsala
Uppsala Monitoring Centre

Ring Vägbeskrivning Webbplats

Uppsala Monitoring Centre (UMC) is an independent, non-profit foundation dedicated to safer use of medicines and vaccines.

UMC advances the science of pharmacovigilance and transforms its practice through technological innovation. Uppsala Monitoring Centre (UMC) is a self-funded, mission-driven, non-profit foundation, that works with the World Health Organization and engages stakeholders throughout the global pharmacovigilance community. As a leader in the research and development of new scientific methods, we explore the risks of medicines and vaccines for patients and offer products and services used by health authorities and the pharmaceutical industry worldwide. For more than 40 years, we have provided scientific advancement and operational support to the WHO Programme for International Drug Monitoring.

30/10/2026

A new research poster, presented at the 2026 OHDSI Global Symposium, presents how UMC researchers and colleagues at the University of Gothenburg mapped Swedish registry data to OMOP. It highlights what worked well, what was challenging, and what's next for the team.

Access it online for more 👉 https://ow.ly/q2kv51021sN

30/10/2026

We're counting down the days, hours, minutes, and seconds to 2026 ⏱️

Anyone with an interest in medicines safety can support the campaign, including healthcare professionals, patient organisations, and regulatory agencies. Together, we can raise awareness of how reporting suspected side effects helps make medicines safer for everyone.

💬 Join the conversation from 2–8 November 2026 – share our posts or download campaign materials, including animations and social media assets, to help us spread the word here 👉 https://ow.ly/BAPj5101BEw

29/10/2026

Evaluating global communications campaigns can be challenging, and is no exception.

A pilot study involving four partners explored how locally relevant goals, evaluation methods, and metrics can support meaningful campaign assessment.

Discover what organisations and regulatory authorities from Colombia🇨🇴, Iraq🇮🇶, Luxembourg🇱🇺, and Sweden🇸🇪 learned during the pilot, and how their findings can inform your campaign this year.

Access the poster for more insights 👉 https://ow.ly/EsX55101qnu

28/10/2026

🎓 Pharmacovigilance is not a one-size-fits-all science or profession.

Career pathways span regulatory authorities, academia, and industry, drawing on people with diverse experiences to support worldwide. With so many options, how do you find your place?

In this episode of , Francesco Salvo and Myriam Salem share their career stories, explain how encounters with patients and mentors inspired them to enter the field, and offer practical advice for those looking to break into .

🎧 Tune in today 👉 https://ow.ly/PhIo50ZXa3Q

26/10/2026

📆 Join us next week for !

Regulators, pharmacovigilance centres, and partners from 130 countries🌍 will join forces to help spread the word about the importance of reporting suspected side effects from medicines.

Let's help make medicines safer for everyone. Learn how you can join the campaign 👉 https://who-umc.org/medsafetyweek/

25/10/2026

How can historical data help improve the triage of safety signals?

Pharmacovigilance covers a vast drug–event space. Disproportionality analysis identifies signals of disproportionate reporting (SDRs) for expert review, but many are dismissed early because they reflect known reactions, bias, or other non-informative patterns.

UMC researchers mapped the scale of signal triage at UMC between 2001 and 2025 to determine historical reasons for early dismissal. Their findings could help focus expert review on drug-event combinations of public health interest.

Explore their findings in this research poster 👉 https://ow.ly/zIjS5100ohx

22/10/2026

How can time-to-onset (TTO) data support signal validation?

Using adverse event reports from VigiBase, Annette Rudolph, Monica Tarapues, Oskar Gauffin, and Qun-Ying Yue explored TTO patterns for four glomerular diseases following COVID-19 vaccination, considering both new-onset and relapse cases. Their findings show how reviewing and characterising TTO data can complement traditional disproportionality analysis during signal validation.

Read their study to find out more at the link below👇

Background Adverse event reports of glomerular diseases (GDs) following coronavirus disease 2019 (COVID-19) vaccination collected nationally have been shared to VigiBase, the global database of adverse event reports for medicines and vaccines. From literature reports, different GDs following COVID-1...

20/10/2026

Advancing the state of the art in duplicate detection in 📚

Duplicate adverse event reports in large-scale pharmacovigilance databases can distort statistical analyses and may mislead clinical assessments. Computational methods are essential for identifying duplicates at scale.

Jim Barrett, Nils Erlanson, Joana Félix, and Niklas Norén introduce a new predictive model, 2025, designed to identify duplicate reports involving drugs and vaccines with improved precision and recall. By leveraging predictive modeling, free-text information, and country-specific features, the model outperforms vigiMatch 2017 while remaining computationally efficient and explainable.

Read the article to discover more 👉 https://ai.jmir.org/2026/1/e95282

19/10/2026

Time-to-onset (TTO) is the time between the start of a medicine or vaccine of interest and the onset of a suspected adverse drug reaction (ADR) and can range from seconds to years. However, ADRs with a long TTO (≥6 months) can be challenging to assess and may go unrecognised.

UMC researchers explore TTO patterns in , with a special focus on long TTO, in a new poster.

Access it online to learn more 👉 https://ow.ly/Glpa50ZVShI

16/10/2026

🎥 Raising awareness of and digitalisation efforts with healthcare professionals and the public can improve reporting rates and help to strengthen reporting systems.

As part of their efforts to build a stronger reporting culture, the Therapeutics Information and Pharmacovigilance Centre (TIPC), part of the Namibia Medicines Regulatory Council (NMRC)🇳🇦, delivers sensitisation workshops across the country to encourage adverse event reporting.

Learn how these workshops deliver positive impact in health districts in the film below👇

Explore the rest of the 'WHO PIDM in Focus' series on YouTube 👉 ow.ly/j81o50QPVtJ

Adress

Bredgränd 7
Uppsala
75320

Öppettider

Måndag	09:00 - 17:00
Tisdag	09:00 - 17:00
Onsdag	09:00 - 17:00
Torsdag	09:00 - 17:00
Fredag	09:00 - 17:00

Telefon

+4618656060

Webbplats

https://who-umc.org/

Aviseringar

Bli först med att veta: vi skickar ett mejl när Uppsala Monitoring Centre publicerar nyheter och kampanjer. Din e-postadress används inte till något annat, och du kan avsluta prenumerationen när som helst.